[HTML][HTML] Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes

R Bejar, KE Stevenson, BA Caughey… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
R Bejar, KE Stevenson, BA Caughey, O Abdel-Wahab, DP Steensma, N Galili, A Raza…
Journal of clinical oncology, 2012ncbi.nlm.nih.gov
Purpose A subset of patients with myelodysplastic syndromes (MDS) who are predicted to
have lower-risk disease as defined by the International Prognostic Scoring System (IPSS)
demonstrate more aggressive disease and shorter overall survival than expected. The
identification of patients with greater-than-predicted prognostic risk could influence the
selection of therapy and improve the care of patients with lower-risk MDS.
Abstract
Purpose
A subset of patients with myelodysplastic syndromes (MDS) who are predicted to have lower-risk disease as defined by the International Prognostic Scoring System (IPSS) demonstrate more aggressive disease and shorter overall survival than expected. The identification of patients with greater-than-predicted prognostic risk could influence the selection of therapy and improve the care of patients with lower-risk MDS.
ncbi.nlm.nih.gov